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Abstract
Background—Hepatocellular carcinoma (HCC) is on the rise worldwide. HCC responds poorly
to chemotherapy. Lapatinib is an inhibitor of EGFR and HER2/NEU both implicated in
hepatocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in
HCC.
Methods—A Fleming phase II design with a single stage of 25 patients with a 90% power to exclude
a true response rate of < 10% and detect a true response rate of ≥30% was utilized. The dose of
lapatinib was 1,500 mg/d administered orally in 28-day cycles. Tumor and blood specimens were
analyzed for expression of HER2/NEU/CEP17 and status of downstream signal pathway proteins.
Results—Twenty-six patients with HCC enrolled on this study. 19% had one prior therapy. Most
common toxicities were diarrhea (73%), nausea (54%) and rash (42%). No objective responses were
observed. Ten (40%) patients had stable disease (SD) as their best response including 6 (23%) with
SD lasting > 120 days. Median progression-free-survival was 1.9 months and median overall survival
12.6 months. Patients who developed a rash had a borderline statistically significant longer survival.
Tissue and blood specimens were available on >90% of patients. No somatic mutations in EGFR
(exons 18–21) were found. In contrast to our previous findings, we did not find evidence of HER2/
NEU somatic mutations. PTEN, P-AKT and P70S6K expression did not correlate with survival.
Conclusions—Lapatinib is well-tolerated but appears to benefit only a subgroup of patients for
whom predictive molecular or clinical characteristics are not yet fully defined.
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The annual mortality rate of hepatocellular carcinoma (HCC) is similar to its annual incidence,
indicating a poor prognosis1. The rising incidence in the U.S. can be largely attributed to the
increase in hepatitis C (HCV)1. Most patients with HCC have advanced disease at the time of
diagnosis with no satisfactory treatment available2–10. The current standard of care in advanced
HCC is sorafenib, an agent recently approved by the Food and Drug Administration based on
a survival advantage versus placebo11.
Potential targets for anticancer therapy in HCC include the epidermal growth factor receptor
(EGFR) and HER2/NEU (EGFR2 or ERBB2), both over-expressed in HCC and directly
implicated in hepatocarcinogenesis. Previous investigations indicate that EGFR is actively
expressed in human HCC cells (in up to 85%), and EGF is required for the growth of those
cells12. A recent study showed that the EGFR inhibitor gefitinib inhibits the growth of
orthotopically implanted HCC tumor in the liver of mice13. In human studies, EGFR inhibition
was found to increase survival in a number of malignancies, although levels of EGFR
expression did not correlate with outcome14–16 The literature contains conflicting data
regarding HER2/NEU expression and its significance in HCC. Several studies have shown that
HER2/NEU is rarely over-expressed in HCC and may not play a role in this disease17–21. Other
studies have demonstrated that HER2/NEU is expressed in a significant number of HCCs, and
may be an independent prognostic factor22,23. We recently reported a novel mutation (H878Y)
in the activating tyrosine kinase domain of HER2/NEU in HCC, and similar to another Asian
study found no EGFR mutations in exons 18–2124,25. Moreover, the EGFR inhibitor erlotinib
demonstrated objective response rates of 0–10% with some patients having prolonged stable
disease26,27.
Lapatinib is a dual inhibitor of EGFR and HER-2/NEU by docking into the ATP binding site
of the 2 receptors28. This results in inhibition of autophosphorylation and downstream signaling
with consequent down-regulation of mitogen-activated protein kinase (MAPK), AKT, and
p70S6 kinase (p70S6K) thereby inhibiting tumor growth29. In early clinical studies, lapatinib
was well tolerated with preliminary evidence of anti-tumor activity in heavily pre-treated
patients with various solid tumors. The most common adverse events included rash (25%) and
diarrhea (27%)28,30. Lapatinib was recently approved by the FDA for use in metastatic breast
cancer31.
Considering all these previous findings, we hypothesized that an inhibitor of both EGFR and
HER2/NEU would have activity in HCC. We conducted and report here a phase II study of
single agent lapatinib in HCC to evaluate its efficacy and tolerability at a dose of 1500 mg
given orally on a daily basis.
Patients and Methods
Eligible patients were required to have histologically confirmed unresectable advanced HCC
and measurable disease per RECIST (Response Evaluation Criteria in Solid Tumors)32, ≤ 1
prior systemic anticancer therapy; patients with prior cryotherapy, radiofrequency ablation,
ethanol injection, transarterial chemoembolization or photodynamic therapy were allowed
provided that greater than six weeks since that therapy and indicator lesion(s) were outside the
area of prior treatment; if the only indicator lesion was inside the prior treatment area, a clear
evidence of disease progression should be demonstrated. Additional criteria included life
expectancy ≥ 12 weeks, ECOG performance status < 2, Child-Pugh score (CP) of ≤ 7 and the
ability to take and absorb oral medications. Patients must have had normal organ function.
Exclusion criteria included patients with prior treatment with EGFR inhibitors, > 450 mg/m2
doxorubicin (given the potential with lapatinib for additional cardiotoxicity, a class effect
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toxicity seen with HER2/NEU inhibitors), major surgery occurring within three weeks prior
to the planned start date, brain metastases, history of malignancy other than HCC within the
previous 3 years except for adequately treated basal cell carcinoma, squamous cell cancer, or
carcinoma of the cervix., uncontrolled intercurrent illness, pregnancy, HIV infection, and
concomitant requirement for medication classified as CYP3A4 inducer or inhibitor.
Study Design
This was a National Cancer Institute (NCI) sponsored phase II, open label, multicenter trial
led by The Ohio State University with the participation of University of Michigan, Virginia
Commonwealth University, H. Lee Moffitt Cancer Center, and University of North Carolina.
Lapatinib was provided by NCI/Cancer Therapy Evaluation Program. The primary objective
of this study was to evaluate the objective response rate (ORR) as defined by RECIST criteria.
Tissue and blood samples were required for all patients. Secondary objectives included
evaluation of toxicity, overall survival, assessment of mutations of EGFR and HER2/neu genes
and measurement of expression of proteins in signaling pathways relevant to lapatinib
including HER2/neu, PTEN, P-Akt, and P70S6K.
Lapatinib administration and dose modifications
The starting dose and schedule of lapatinib was 1,500 mg/d orally without interruption in 28
days cycles. There were 3 levels of dose reductions planned (1250, 1000 and 750 mg/d) with
patients taken off study if they needed additional dose reductions.
Assessment of response and toxicity
Radiological assessment was done by CT or MRI (as long as the same consistent measure was
used serially) every 8 weeks and responses were measured according to the RECIST criteria.
Toxicities were defined by the NCI-CTCAE version 3.0.
Correlative studies
Tissue and Blood acquisition
Either fresh tissue or paraffin embedded tissue from tumor blocks and adjacent normal tissue
were required from patients before enrolling on this study. One blood sample (ACD 10 ml tube
used for DNA analysis from peripheral blood mononuclear cells) was obtained before patients
enrolled on study with a goal to examine germline mutations.
Immunohistochemistry analysis of PTEN, P-AKT and p70S6K
3–5-micron sections of tumor tissue were immunostained with monoclonal antibody 6H2.1
specific for the terminal 100 amino acids of human PTEN (Cascade Bioscience), polyclonal
antibody against P-AKT and total AKT (Upstate Biotechnology), or monoclonal antibody
against P70S6K and P70S6K (Mab 1A5, Cell Signaling) utilizing a modified avidin-biotin
complex technique with antibody dilutions of 1:50– 1:25033,34. For p70S6K and pAKT IHC,
the MDA-MB-468 cells were used in a cytoblock as a positive control. The cells were fixed
and processed in the same fashion as a tissue biopsy (30 min in 10% NBF, standard tissue
processing per our histology core). For PTEN, we optimized the protocol for renal tissue, and
a positive case was selected and run with each batch. For each batch of IHC run, the appropriate
control was run with the same conditions and concentrations, and a negative control was done
by following the conditions but substituting the antibody incubation with a “null” PBS
incubation. The sections were independently scored by NJ and CE after which a “consensus”
scoring session was performed (no discrepancies noted). Most sections had internal controls
(normal tissue). A consistent positive control for PTEN are endothelial cells and so when the
tumor expressed to similar intensity as endothelial cells in the same specimen, it was scored
Bekaii-Saab et al. Page 3













as 2+, as is routine34. Decreased expression was scored 1+ and no expression 0. Phosphoprotein
expression was compared to total protein expression for each of AKT and P70S6K between
HCC and non-neoplastic cells, and scored as no expression, slightly increased (1+) and
increased (2+) expression. Furthermore, expression of PTEN, AKT and P-AKT was noted to
be nuclear or cytoplasmic in the carcinoma cells.
Assessment of HER2/NEU and enumeration of chromosome 17 (CEP17) by Fluorescence in
situ hybridization (FISH)
FISH was done on formalin-fixed paraffin embedded tissue sections (FFPET). 4–6 um sections
were placed on positively charged slides, dried and baked overnight at 56° C. The sections
were deparaffinized in Hemo-De, dehydrated and air-dried. Subsequently the sections were
treated with Pretreatment and Protease Solutions (Abbott Molecular, Downers Grove, IL)
according to the manufacturer’s protocol. LSI HER2/NEU and CEP17 probe mixture (Abbott
Molecular, Downers Grove, IL) was applied to the tissue and co-denaturation and hybridization
took place using HyBrite (Abbott Molecular, Downers Grove, IL). The following day, slides
were washed, dried and counterstained with DAPI. Specimens were analyzed using Zeiss
Axioscope-40 equipped with appropriate filters. Fifty cells per sample were scored. A ratio of
> 2 of HER2/NEU to CEP17 probe signals was considered amplified. Control samples were
run concurrently with the patients’ samples.
EGFR and HER2/NEU mutation screening
Genomic DNA extracted from FFPET or frozen HCC were treated with sodium dodecyl sulfate
and digested with proteinase K, followed by sodium chloride precipitation of protein35. The
DNA in the supernatant was further purified and recovered by ethanol precipitation. Exons 18
to 21 (including exon-intron junctions and flanking intronic regions) of EGFR and exons 19
to 24 of HER2/NEU were amplified by PCR24. After PCR amplification, primers and free
nucleotides were removed by digestion with Exonuclease I and Bacterial Antarctic Alkaline
Phosphatase (New England Biolabs, Beverly, MA). PCR products were cycle sequenced at the
Ohio State University Plant-Microbe Genomics Facility, using Applied Biosystems reagents
on an ABI 3730. The resulting DNA sequences were compared using the online multiple
sequence alignment program ClustalW2 (https://www.ebi.ac.uk/Tools/clustalw2/index.html).
Sequence differences were independently verified by PCR amplification and cycle sequencing
in the opposite direction.
Statistical Methods
The primary endpoint of this trial was the proportion of patients demonstrating objective
response [ORR] as defined by RECIST. Based on results from studies of erlotinib in HCC
which reported response rates of up to 9%, the trial was designed to detect objective response
rates of ≤ 10% versus ≥ 30%. Sample size was based on a single stage Fleming phase II
design36,37 with a 90% power and a 10% type I error. Lapatinib would be considered
uninteresting if the true response probability was less than 10% and that the regimen was worthy
of further study if the true response probability was ≥ 30%. With this design, an observed
response rate of 20% or greater would be considered interesting. Target accrual was 25 patients.
The secondary endpoints included median progression free survival (mPFS) and overall
survival (mOS). OS was determined from the date of the start of Lapatinib therapy to death
from any cause or the date of last observation. PFS was calculated from the date of start of
Lapatinib therapy to disease progression or death, whichever occurred first. Actuarial survival
curves were estimated using the method of Kaplan-Meier and 95% CIs for the medians were
provided. Log-rank test examined the relationship between the survival and the presence of
rash, or with HCV, or the expression level of different proteins.
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Patient Characteristics (Table 1)
Twenty-six patients were enrolled between the dates of March 3, 2006 and May 14, 2007.
Patient characteristics are included in Table 1. Of the 26 patients enrolled, 25 were evaluable
for response (one patient passed away prior to restaging). All 26 patients were evaluable for
toxicity and survival analysis.
Treatment Toxicity (Table2)
Only 12% of patients required dose reductions. The most common toxicities included diarrhea
(73%), nausea (54%) and rash (42%). Grade 3 toxicities were noted in only 3 patients and
included diarrhea (2), rash (1) and acute renal failure (1). All toxicities were reversible.
Treatment Efficacy (Table 3, Figure1 and Figure2)
A median of 2 cycles were administered (range 1–14). No patients had an objective response.
10 (40%) patients had stable disease (SD) including 6 (23%) with SD ≥ 120 days and 2 (8%)
with SD > 1 year. Those 2 patients with the longest prolongation of disease stabilization were
noted to both have a rash and be non-AFP secretors.. mPFS was 1.9 months (95% CI; 1.8–3.6)
and mOS was 12.6 months (95% CI; 7.8–22.4 months) (Figure 1).
Patients who developed a rash had a mPFS (2.4 months ; 95% CI; 1.8–4.7 months) that is
numerically superior to the mPFS of patients without a rash (1.8 months ;95% CI; 1.4–4.9
months), although the difference was not statistically significant (p= 0.25) (Figure 2a). mOS
for patients with a rash was superior (16.2 months; 95% CI; 10.9-NA months) to patients who
did not develop a rash (8.7 months; 95% CI; 1.8–16.0 months), and the difference was
borderline statistically significant (p=0.07) (Figure 2b). Patients with HCV had a mOS of 11.8
months (95% CI; 2.3–22.4 months) and a mPFS of 3.6 months (95%CI; 1.8–5.2 months). When
comparing these results to those of the general study population, mPFS trended to be better
with HCV but the differences in PFS and OS curves were not statistically significant (p=0.73
for PFS and p=0.83 for OS).
Biological Markers
Tissue and blood specimens were available for 24 out of 26 (92%) patients
EGFR/ HER2/NEU mutations and protein expression
No somatic mutations in EGFR (exons 18–21) were found. We did not find evidence of HER2/
NEU somatic mutations. In addition, HER2/NEU copy number was not elevated in our analysis
using FISH. IHC also did not reveal increased HER2/NEU protein expression.
Immunohistochemistry analysis of PTEN, P-AKT and p70S6K (Table 4)
IHC staining was used to analyze expression and subcellular (nuclear or cytoplasmic)
localization of PTEN, P-AKT and P70S6K. Univariate Cox regression models were fitted for
different proteins (PTEN (nuclear component), PTEN (cytoplasmic component), P-AKT
(nuclear component), P-AKT (cytoplasmic component), P70S6K (nuclear component), and
P70S6K (cytoplasmic component) with no statistical evidence of correlation with OS (p-values
are 0.49, 0.97, 0.66, 0.30, 0.95 and 0.65 respectively) or PFS (p-values are 0.18, 0.69, 0.88,
0.17, 0.61 and 0.61 respectively). Using Fisher exact test we found no correlation (for each of
the above mentioned proteins) between the lack of expression (score 0 vs. scores 1 and 2), or
expression level (score 0 vs. 1 vs. 2) and prolonged stable disease (defined as either ≥ 3 or ≥4
months). In addition, we were unable to show a correlation between expression level of protein
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and PFS or OS. Individual results for immunohistochemistry analysis results and individual
results for PFS and OS are presented in Table 4.
Discussion
HCC represents one of the most challenging cancers. The rationale for this study was based
on the demonstration of a role for EGFR and HER2/NEU signaling pathways in the
carcinogenesis of HCC.
Results from this study revealed minimal activity of lapatinib as a single agent in treating
patients with advanced HCC based on the lack of objective responses, the primary endpoint of
the study. The choice of this primary endpoint may not have been optimal given the difficulty
in assessing disease response by RECIST criteria38. However, the lack of activity of lapatinib
is also supported by the short mPFS and relatively modest proportion of patients with stable
disease. Sorafenib had a reported ORR of 2.3%39. However, the median time to radiologic
progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group. Other
studies examining the role of EGFR inhibitors reported ORR ranges of 0–9% (Table 516,27,
-40–42). In our study, we reported a mPFS of 1.9 months consistent with that reported from
another study with lapatinib in HCC41. This uninteresting mPFS could be confounded by
factors such as inclusion of patients with Child’s Pugh score B (27%) and prior therapy in 19
% of patients. mOS with lapatinib was one of the highest reported in the literature. This may
be partly explained by the use of sorafenib following progression in 40% of our patients, an
agent with a known survival advantage in HCC39. Also noted, and similar to an effect which
has been observed with EGFR inhibitors in a variety of other malignancies 15,43,44, was that
survival was significantly improved in the subgroup of patients who developed a rash. This
improvement in survival does not seem to be confounded by therapy beyond progression since
38% of patients who developed a rash received sorafenib vs. 54% in those who did not have a
rash. This finding suggests a potential benefit from EGFR inhibition but development of rash
may also be prognostic (i.e. patients able to develop rash may have a more favorable outcome
regardless of the activity of the agent).
Another interesting observation from our study is that 3 out of the 4 patients with AFP lower
than ULN (AFP-negative) had stable disease longer than 4 months including the only 2 patients
with disease control longer than 12 months. Improved survival has been previously reported
in patients with HCC whose AFP was normal when compared to those with elevated serum
marker levels 45,46. This prognostic finding may be related to the background liver disease for
most patients with HCC and the prevalence of Child’s Pugh score A seems to be higher in
AFP-negative tumors45. Indeed, our AFP-negative patients were all found to have more
favorable Child’s Pugh scores (All 4 had a CP score of 5). It is unclear whether there is any
added benefit in those patients from EGFR inhibition, and this question should be addressed
in future randomized studies.
Interestingly, mPFS trended to be higher in patients with HCV although the differences in PFS
and OS curves were not statistically significant with lapatinib when compared to the general
population unlike what was noted in patients receiving sorafenib37,47.
The drug was overall well tolerated with only 12% of patients requiring a dose reduction. The
toxicity to lapatinib was predominantly gastrointestinal followed by cutaneous similar to other
drugs that target EGFR/HER1. Of note, patients with Child’s Pugh B (7) did not have any
worse toxicity than those with Child’s Pugh A (5 and 6).
We also performed a set of accompanying correlative studies of relevance to the targeted
pathways. A strength of our study is the acquisition of tissue in > 90% of all patients enrolled.
Similar to our previous findings24, we found no activating EGFR mutations on this study.
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However, unlike our previous published findings24, we found no activating somatic mutations
in HER2/NEU. In addition, HER2/NEU copy number was not found to be elevated in our
analysis using FISH (nor protein expression by IHC staining). Based on these observations,
therefore, dual-specificity EGFR-TKIs may in fact be predicted to not be more efficacious than
EGFR-TKI. We chose to examine PTEN and the AKT signaling pathway as there has been
ample evidence in other solid tumors that loss of normal PTEN function or activation of the
AKT pathway would predict for resistance to EGFR-TKIs even in the context of EGRF
activation48. However, levels of PTEN, P-AKT and P70S6K, did not correlate with progression
free survival or overall survival in the current study. As part of prioritizing the correlative
studies we performed, we decided not to include EGFR expression levels or to look for
KRAS mutations. EGFR expression has been documented in multiple studies to occur at high
levels in HCC and did not seem to correlate with response14–16. Somatic mutations in the genes
encoding the molecules in the KRAS pathway are rarely seen in HCC47 and do not seem to
have a predictive role for EGFR inhibition in this disease49.
In conclusion, dual EGFR inhibition with lapatinib has minimal activity in HCC, although
certain subgroups of patients (such as those who developed a rash, an effect attributable to
EGFR/HER1 inhibition) had a more favorable outcome when compared to the overall study
population. As such, results from this trial and others (table 4) encourage the continued
development of a strategy to target EGFR-TK blockade as a single modality or preferably in
combination (with VEGF or mTOR inhibitors) for treating HCC. Although our attempt to
identify molecular or genetic predictors of a more favorable outcome was unsuccessful,
enrichment strategies must continue to be investigated to achieve similar results to those in
lung and colon cancer. Two possible mechanisms for EGFR inhibitor-related skin toxicity have
been previously postulated. The first (likely) is more straightforward and relates to direct
inhibition of cutaneous EGFR. The other (unlikely) relates the development of a rash as a
manifestation to a systemic immunologic reaction50. Since HCC is a heterogeneous disease
with multiple redundant signaling pathways and etiologies, the role of certain pathways may
be different in various subgroups (HCV, for example). Future studies should consider a
randomized approach with appropriate stratifications (by Child’s Pugh score, AFP levels,
presumed etiology of HCC etc…).
Statement of Translational Relevance
The rationale for this study was based on the demonstration of a role for EGFR and HER2/
NEU signaling pathways in the carcinogenesis of HCC. Lapatinib appears to benefit only
a subgroup of patients for whom predictive molecular or clinical characteristics are not yet
fully characterized. For example, we found that although dual EGFR inhibition has minimal
activity in HCC, certain subgroups of patients such as those who developed a rash, an effect
attributable to EGFR/HER1 inhibition, had a significantly more favorable outcome when
compared to the overall study population. This finding suggests a potential benefit from
EGFR inhibition.. Other considerations from our results include findings that suggest that
future studies should consider a randomized approach with appropriate stratifications (AFP
levels, etiology etc…). Final results of accompanying correlative studies are also presented.
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Progression Free Survival (PFS) and Overall Survival OS Curves
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Figure 2a: Progression Free Survival (PFS) According to Rash
Figure 2b: Overall Survival (OS) According to Rash
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Table 1
Patient Demographics and Characteristics
N 26
    Male 18
    Female 8
Age (years)
    Median 58
    Range 29–81
Race/Ethnicity
    White 20
    African American 4
    Asian 1
    Other 1
ECOG
      0 12
      1 14
Prior Treatments
    X-Ray Treatment 3
    Chemo-embolization 2
    Surgery 16
    Chemotherapy 3
Sites of Metastasis
    Lymph Nodes 8
    Lungs 8
    Spine 1
    Bone 1
    Adrenal Gland 1
    Peritoneal Mets 1
    Hepatic Mets 1
    Chest Wall 1
Etiology
    Hepatitis B 3
    Hepatitis C 8
    Alcohol 4






    > ULN 21
    ≤ULN 4
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Table 2
Toxicities (N=26)*
Toxicity All Toxicities Grade 1 Grade 2 Grade 3
Diarrhea 19 14 3 2
Nausea 14 10 4 0
Rash 13 10 2 1
Fatigue 11 8 3 0
Vomitting 7 5 2 0
Alkaline Phosphatase 5 4 1 0
ALT 5 3 2 0
AST 4 1 3 0
Hemoglobin 4 4 0 0
Hypoalbunemia 3 3 0 0
Leukpenia 2 2 0 0
Anorexia 3 2 1 0
Platelets 2 2 0 0
Creatinine 2 2 0 0
Hypocalcemia 2 2 0 0
Itching 2 2 0 0
Reflux 2 2 0 0
*
There were no grade 4 toxicities

















  Overall Response Rate 0 (0)
  Stable Disease 10 (40)
    Stable Disease > 120 days 6 (23)
  Poregressive Disease 16 (64)
  Non-evaluable 1(4)
Median Progression Free Surival 1.9 mos (95% CI; 1.8–3.6)
    − Rash 1.8 mos
    + Rash 2.4 mos*
Median Overall Survival 12.6 mos (95% CI; 7.8–22.4)
    −Rash 8.7 mos
    + Rash 16.2 mos^
^
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